Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Weekly
Analytics
Regulatory and Compliance Updates news
(page 4)
6 November 2025
Novo Nordisk and U.S. Administration to Lower GLP-1 Costs and Expand Access
Novo Nordisk to lower semaglutide prices in 2026, expand Medicare Part D coverage, and expects a slight negative impact on global sales growth.
6 November 2025
Lilly and U.S. Government Expand Access to Obesity Drugs
Medicare beneficiaries to access obesity drugs at $50/month. LillyDirect offers self-pay options. FDA approval pending.
6 November 2025
Johnson & Johnson's CAPLYTA® Approved by FDA for Major Depressive Disorder Treatment
FDA approves CAPLYTA® as adjunctive therapy for major depressive disorder, showing significant symptom improvement and safety in trials, with potential for remission.
6 November 2025
Clariant and FUHUA Form Joint Venture for Flame Retardants
The venture will produce halogen-free flame retardants in China, addressing regulatory needs. Clariant expands capacity with a CHF 100M investment and a new production line in Cangzhou.
6 November 2025
Sasol Develops Methane Rich Gas Solution for South Africa's Post-2028 Gas Supply
Sasol plans to supply Methane Rich Gas from 2028-2030 to bridge the gas supply gap, pending regulatory approval, while transitioning to LNG for long-term needs.
5 November 2025
Hyundai Transys and BASF Develop Modular Seat with Elastollan TPU
The new seat uses Elastollan TPU with SCF foaming for customizable, sustainable automotive interiors, offering recyclability, reduced VOCs, and energy efficiency.
News type
New Projects and Expansions
New Projects and Expansions
Project Updates and Milestones
Project Updates and Milestones
Mergers, Acquisitions, and Partnerships
Mergers, Acquisitions, and Partnerships
Innovation and Product Development
Innovation and Product Development
Operational Changes and Investments
Operational Changes and Investments
Sustainability and Environmental Initiatives
Sustainability and Environmental Initiatives
Financial Performance and Strategy
Financial Performance and Strategy
Executive Appointments and Governance Changes
Executive Appointments and Governance Changes
Regulatory and Compliance Updates
Regulatory and Compliance Updates
Workforce and Corporate Social Responsibility (CSR)
Workforce and Corporate Social Responsibility (CSR)
Crisis and Risk Management
Crisis and Risk Management
The right choices in the European chemical industry
Save time with
chemXplore Analytics
Learn more
5 November 2025
Novo Nordisk's Wegovy® Helps Users Meet Health Targets, Reducing Obesity Risks
Wegovy® users achieved BMI and waist targets, improving cardiovascular health and reducing obesity-related risks, as shown in the STEP UP trial.
5 November 2025
EU Boosts Climate Goals Before COP30
The EU commits to reducing GHG emissions by 66.25-72.5% by 2035 and 90% by 2040, aiming for climate neutrality by 2050, ahead of COP30.
5 November 2025
Novo Nordisk Unveils New Oral Semaglutide Analyses at ObesityWeek 2025
Oral semaglutide 25 mg shows improved blood sugar control, cardiovascular risk factors, and weight loss efficacy, comparable to injectable form, across various patient groups.
4 November 2025
Securing Biogas Plant Connections to Gas Networks
Propose regulations to ensure efficient, cost-effective biogas plant connections to gas networks, supporting climate goals and economic viability.
4 November 2025
BASF Introduces Cavipor Clay Foam for Insulation Market
Cavipor clay foam, now approved for floors and roofs, enhances energy efficiency and sustainability in building insulation, with easy application and recyclability.
4 November 2025
Asahi Kasei's Nefecon Added to KDIGO Guidelines for IgA Nephropathy Treatment
Nefecon's inclusion in KDIGO 2025 guidelines highlights its role in IgAN treatment, supporting Asahi Kasei's strategic growth in healthcare.
3 November 2025
Clariant Wins Petrobras Best Suppliers Award for Chemicals
Clariant excels in quality, ESHA, delivery, and contract management, scoring 5.7/6 on Petrobras's Supplier Performance Index, enhancing its reliability and performance.
3 November 2025
Takeda's Dengue Vaccine Proven Effective for 7 Years
QDENGA shows long-term safety and efficacy, reducing dengue cases and hospitalizations. Approved in 41 countries, it remains effective across all virus serotypes with no new safety issues.
3 November 2025
Uniper Sells Uniper Wärme GmbH to Steag Iqony Group
The sale fulfills EU conditions for Uniper's stabilization package. Uniper Wärme serves 14,400 customers with a 750 km district heating network using CHP and eco-friendly heat sources.
3 November 2025
Roche's Gazyva Shows Significant Disease Reduction in Lupus Study
Phase III study shows Gazyva meets primary and secondary endpoints in SLE, potentially setting a new care standard by targeting B cells and reducing organ damage risk.
31 October 2025
Johnson & Johnson Seeks FDA Approval for STELARA in Pediatric Ulcerative Colitis
sBLA submitted for STELARA to treat pediatric ulcerative colitis, backed by Phase 3 UNIFI Jr trial data, aiming to expand treatment options for children.
31 October 2025
Iberdrola Acquires PREVI's 30.29% Stake in Neoenergia
Iberdrola now controls 84% of Neoenergia, investing €1.92 billion. Neoenergia leads Brazil's distribution with 40M customers and 3,800 MW renewable capacity.
30 October 2025
LANXESS Launches Sustainable Additive for Extreme Pressure
Additin RC 2515 now uses over 80% sustainable materials, reducing PCF by 34%. It excels in extreme pressure applications and is ISCC PLUS-certified.
30 October 2025
EIB Provides €90 Million for TVO's Olkiluoto Nuclear Plant Upgrades
The EIB funds upgrades to enhance safety and reliability of Olkiluoto's nuclear units, supporting Finland's energy independence and EU climate goals.
30 October 2025
BASF and ETH Zurich: Recycling Automotive Waste into High-Value Feedstock
Recycling automotive shredder residue with biomass reduces emissions, offers new feedstocks, and requires supportive policies for mixed waste gasification.
29 October 2025
Johnson & Johnson to Conduct Study Comparing IMAAVY™ and Alternative FcRn Blocker for gMG
The EPIC study will compare IMAAVY™ to efgartigimod in gMG patients, including a treatment-switch arm. Vibrance-MG data shows sustained IgG reduction and disease control in pediatric patients.
29 October 2025
Merck and Eisai Update on LEAP-012 Trial for Hepatocellular Carcinoma
The LEAP-012 trial showed no overall survival benefit for the treatment, but progression-free survival improved. The study is closed, and further data analysis is ongoing.
29 October 2025
Merck's KEYTRUDA Approved in EU for Treating Resectable LA-HNSCC
KEYTRUDA gains EU approval as the first anti-PD-1 therapy for resectable LA-HNSCC with PD-L1 expression, based on KEYNOTE-689 results.
28 October 2025
Merck and Eisai's WELIREG and LENVIMA Improve PFS in Advanced Renal Cell Carcinoma Trial
The trial showed significant PFS and ORR improvements with WELIREG and LENVIMA in advanced RCC patients post anti-PD-1/L1 therapy, with consistent safety profiles.
28 October 2025
Roche's Gazyva Shows Positive Phase III Results in Pediatric Nephrotic Syndrome
Gazyva achieved sustained remission in young nephrotic syndrome patients, reducing steroid use. No new safety issues. Data to be shared with health authorities.
27 October 2025
Dow's Freeport MDI Facility Achieves ISCC PLUS Certification
The Freeport facility now offers bio-circular isocyanates with ISCC PLUS certification, enhancing sustainability and supply chain transparency for various industries.
27 October 2025
Merck's WINREVAIR Approved by FDA for Expanded PAH Treatment
WINREVAIR, now approved for PAH, improves exercise capacity, reduces clinical worsening risks, and shows significant efficacy in the ZENITH trial. Monitor hemoglobin and platelets during treatment.
27 October 2025
Johnson & Johnson's Icotrokinra Shows Therapeutic Benefit and Safety in Ulcerative Colitis
Icotrokinra shows sustained clinical benefits and safety in ulcerative colitis, with Phase 3 trials underway for broader applications.
27 October 2025
Johnson & Johnson's TREMFYA® Shows Two-Year Remission in Crohn's Disease
TREMFYA® maintains remission in Crohn's disease over 96 weeks, with consistent safety and efficacy in both subcutaneous and intravenous regimens.
← Previous
Next →
